Placebo matched to Rifampin — Competitive Intelligence Brief

Placebo matched to Rifampin (Placebo matched to Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial RNA polymerase inhibitor. Area: Infectious Diseases.

phase 3 Bacterial RNA polymerase inhibitor Bacterial RNA polymerase Infectious Diseases Small molecule

Target snapshot

Placebo matched to Rifampin (Placebo matched to Rifampin) — Hamilton Health Sciences Corporation. Rifampin is a bacterial RNA polymerase inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matched to Rifampin TARGET	Placebo matched to Rifampin	Hamilton Health Sciences Corporation	phase 3	Bacterial RNA polymerase inhibitor	Bacterial RNA polymerase
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifaximin and loperamide	Rifaximin and loperamide	The University of Texas Health Science Center, Houston	marketed	Antibiotic + antidiarrheal combination	Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide)
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)
PB 6 doses - Rifampicin and Dapsone	PB 6 doses - Rifampicin and Dapsone	University of Brasilia	marketed	Antileprosy combination therapy	Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone)
Rifamycin-containing regimen	Rifamycin-containing regimen	National Taiwan University Hospital	marketed	Rifamycin antibiotic	Bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial RNA polymerase inhibitor class)

1. Hamilton Health Sciences Corporation · 1 drug in this class
2. Nantes University Hospital · 1 drug in this class
3. Radboud University Medical Center · 1 drug in this class